Chronic Heart Failure: PBAC Recommends Empaglif...

April 14, 2023

Introduction: The Pharmaceutical Benefits Scheme (PBS) included Empagliflozin, a sodium glucose co transporter 2 (SGLT2) inhibitor, for chronic heart failure (CHF) treatment with reduced ejection fraction ...

When you collaborate with VSH Foundation, it's like unlocking a new dimension in healthcare innovation.

Our research synergizes with your vision, combining expertise in health economics, policy analysis, advanced analytics, and AI applications in healthcare. You’ll witness the fusion of cutting-edge methodologies and real- world impact, as we work together to transform healthcare systems and improve patient outcomes globally.

CORRESPONDENCE ADDRESS

PO Box 8547, #95478, Boston, MA 02114, USA

© 2024 Value Science Health Foundation. All rights reserved.
Made with by Frogiez